Biolase, Inc. (BIOL) News

Biolase, Inc. (BIOL): $4.58

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter BIOL News Items

BIOL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BIOL News Highlights

  • For BIOL, its 30 day story count is now at 2.
  • Over the past 13 days, the trend for BIOL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • NC are the most mentioned tickers in articles about BIOL.

Latest BIOL News From Around the Web

Below are the latest news stories about Biolase Inc that investors may wish to consider to help them evaluate BIOL as an investment opportunity.

Is BIOLASE (NASDAQ:BIOL) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Yahoo | February 10, 2022

36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022

RALEIGH, NC / ACCESSWIRE / January 28, 2022 / The Winter Wonderland Best Ideas Virtual Investor Conference will take place on February 8th \- 11th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The virtual conference begins on Tuesday, February 8th, 2022, with company presentations beginning at 8:30 am Eastern Time.

Yahoo | January 28, 2022

BIOLASE Announces Continuation of Exclusive Collaboration with BMW Performance Center West (BMW PCW) and Winner of BMW Sweepstakes

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced a continuation of their collaboration with BMW Performance Center West (BMW PCW) at The Thermal Club near Palm Springs, to offer dentists the unique opportunity to experience two state-of-the-art pieces of technology; the Waterlase dental laser and BMW award-winning vehicles.

Yahoo | January 20, 2022

Maxim Group Thinks Biolase’s Stock is Going to Recover

Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Biolase (BIOL – Research Report) yesterday and set a price target of $2.00. The company's shares closed last Tuesday at $0.41, close to its 52-week low of $0.27. According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 8.1% and a 38.2% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as ReShape Lifesciences, Milestone Scientific, and Dermata Therapeutics. Biolase has an analyst consensus of Moderate Buy, with a price target consensus of $2.00, a 412.8% upside from current levels.

Christine Brown on TipRanks | January 11, 2022

Biolase (BIOL) Gets a Buy Rating from Colliers Securities

In a report released today, Kyle Bauser from Colliers Securities reiterated a Buy rating on Biolase (BIOL – Research Report), with a price target of $2.00. The company's shares closed last Monday at $0.39, close to its 52-week low of $0.27. According to TipRanks.com, Bauser is a 2-star analyst with an average return of 0.3% and a 45.5% success rate. Bauser covers the Healthcare sector, focusing on stocks such as Apollo Medical Holdings, Chembio Diagnostics, and Semler Scientific. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biolase with a $2.00 average price target.

Catie Powers on TipRanks | January 10, 2022

BIOLASE ANNOUNCES POSTIVE PRELIMINARY REVENUE RESULTS FOR 2021 FOURTH QUARTER; ENTERS 2022 WITH SIGNIFICANT MOMENTUM

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced preliminary 2021 fourth quarter revenue results that are significantly above fourth quarter revenue for both 2020 and pre-COVID 2019. The Company will announce the results for the fourth quarter and full year ended December 31, 2021 in the first half of March 2022.

Yahoo | January 10, 2022

Colliers Securities Thinks Biolase’s Stock is Going to Recover

In a report released today, Kyle Bauser from Colliers Securities reiterated a Buy rating on Biolase (BIOL – Research Report), with a price target of $2.00. The company's shares closed last Thursday at $0.40, close to its 52-week low of $0.27. According to TipRanks.com, Bauser is a 2-star analyst with an average return of 0.3% and a 45.5% success rate. Bauser covers the Healthcare sector, focusing on stocks such as Chembio Diagnostics, Semler Scientific, and Motus Gi Holdings. Biolase has an analyst consensus of Moderate Buy, with a price target consensus of $2.00.

Brian Anderson on TipRanks | January 7, 2022

BIOLASE and EdgeEndo Announce FDA 510(k) Clearance of New EdgePRO Laser-Assisted Microfluidic Irrigation Device for Endodontists

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, and EdgeEndo, a global leader in commercializing endodontic products, announced today the FDA 510(k) clearance of the EdgePRO system for endodontists seeking a more effective cleaning and disinfection alternative within root canal procedures. The new laser-assisted microfluidic irrigation device offers an advanced solution to current cleaning and disinfection techniques, without disrupting procedure workflow or adding substantial

Yahoo | January 6, 2022

BIOLASE TO PRESENT AT THE H.C. WAINWRIGHT BIOCONNECT VIRTUAL INVESTOR CONFERENCE

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced it will participate in the H.C. Wainwright BIOCONNECT Virtual Investor Conference being held on January 10-13, 2022. BIOLASE President and CEO John Beaver is scheduled to deliver a formal presentation and host virtual one-on-one meetings with investors.

Yahoo | January 5, 2022

7 of the Best Penny Stocks Under $3 for 2022 to Buy Now

Penny stocks under $3 are full of potential and potential pitfalls.

Alex Sirois on InvestorPlace | December 31, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.53 seconds.